Lack of clarity on safety and efficacy causes shareholders to decamp.
Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
The clinical hold for Biomarin’s phenylketonuria project comes on the heels of an FDA adcom to discuss gene therapy toxicity.
AT132 has prompted more safety concerns, this time at a lower dose than before.
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
One-year data look encouraging, but etranadez will now not be filed until 2022.